Sanofi: positive results for mRNA-based vaccine
(CercleFinance.com) - Sanofi has announced positive interim results from a Phase I/II study of its Covid-19 messenger RNA (mRNA) vaccine candidate, confirming the potential of Translate Bio's recently acquired platform.
The initial Phase I/II data showed a high seroconversion rate for all three doses tested, as well as a safety profile comparable to that of other unmodified mRNA Covid-19 vaccines.
The healthcare group intends to accelerate the transformation of the recently acquired platform to modified mRNA, with the goal of a quadrivalent modified mRNA influenza vaccine in the clinic in 2022.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The initial Phase I/II data showed a high seroconversion rate for all three doses tested, as well as a safety profile comparable to that of other unmodified mRNA Covid-19 vaccines.
The healthcare group intends to accelerate the transformation of the recently acquired platform to modified mRNA, with the goal of a quadrivalent modified mRNA influenza vaccine in the clinic in 2022.
Copyright (c) 2021 CercleFinance.com. All rights reserved.